



Prof. Dr. med. Jens Bedke
Vice Chairman, Department of
Urology, University of Tübingen,
Germany

Prof. Jens Bedke is the Vice Chairman at the Department of Urology at the University of Tübingen, Germany, where his main research areas include uro-oncology, tumor-immunology, and metabolomics.

He has a long-standing record with more than 190 publications in major PubMed indexed journals like NEJM, Lancet, and Lancet Oncology. His clinical focus is surgical therapy of uro-oncologic tumors with a special emphasis on radical prostatectomy, cystectomy, robotic kidney sparing surgery, and the medical treatment of genitourinary cancers.

Dr. Bedke is a member of several national and international societies including the European Association of Urology (EAU), American Urological Association (AUA), and the editorial board of the "World Journal of Urology." He serves as AUO board member of the German Cancer Society, a working group of uro-oncology. Additionally, he is a spokesperson for the German Renal Cancer Study Group, and a member of the German Testicular Cancer Study Group (GTCSG) of the German Cancer Society. He also is a board member of the EAU Renal Cell Carcinoma (RCC) guideline panel. He actively participates in clinical trials as a principal investigator, including the current immunotherapy (IO) and tyrosine kinase inhibitors (TKI) combinatory trials in renal cell carcinoma like the Phase III CheckMate -9ER trial, which he co-authored.

During the ESMO interviews, Prof. Jens Bedke will be sharing a deep-dive into the CheckMate -9ER data.